# Clinical Trial in Patients Who Have Suffered a Heart Attack and Who Have Undergone Catheterization Treated With Levosimendan

Study · id `cardio:ct-nct03699215` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03699215](<https://clinicaltrials.gov/study/NCT03699215>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03699215

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 184 participants.

## Technical summary

Registry record NCT03699215. Randomized; triple masking; primary purpose treatment. Start 2018-11-17 (actual); primary completion 2020-04-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 184 participants (planned count; ClinicalTrials.gov record NCT03699215, source copy `cardio:ctgov-nct03699215-2021-02-11`, retrieved 2026-10-26)
- Started: 2018-11-17 (actual) (ClinicalTrials.gov record NCT03699215, source copy `cardio:ctgov-nct03699215-2021-02-11`, retrieved 2026-10-26)
- Primary completion: 2020-04-30 (actual) (ClinicalTrials.gov record NCT03699215, source copy `cardio:ctgov-nct03699215-2021-02-11`, retrieved 2026-10-26)
- Completion: 2021-12-30 (anticipated) (ClinicalTrials.gov record NCT03699215, source copy `cardio:ctgov-nct03699215-2021-02-11`, retrieved 2026-10-26)
- Countries: Spain (ClinicalTrials.gov record NCT03699215, source copy `cardio:ctgov-nct03699215-2021-02-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03699215-2021-02-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: Clinical Trial in Patients Who Have Suffered a Heart Attack and Who Have Undergone Catheterization Treated With Levosimendan
- Acronym: LEVOCEST
- Condition: ST Elevation Myocardial Infarction
- Intervention (Drug): Levosimendan
- Intervention (Drug): Placebos
- Lead sponsor: Hospital Universitario de Canarias
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)

## Provenance

Content hash: 18ccf9c91b89cc9ec5512d1888327fe7ff948ff09f773c7df65d56f504c7a763
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
